Licensed and Manufactured by Pfizer Catalog No.S2830

For research use only.

Clindamycin inhibits protein synthesis by acting on the 50S ribosomal, used for the treatment of bacterial infections.

Clindamycin Chemical Structure

CAS No. 18323-44-9

Purity & Quality Control

Choose Selective Bacterial Inhibitors

Biological Activity

Description Clindamycin inhibits protein synthesis by acting on the 50S ribosomal, used for the treatment of bacterial infections.
In vitro

Clindamycin is a semisynthetic analogue of lincomycin. Clindamycin primarily inhibits the initiation of peptide chain synthesis by deregulating enzyme-catalyzed initiation of peptide bounds. Clindamycin appears to have a modest effect on protein synthesis by certain mammalian cells. [1] Clindamycin is active against most gram-positive aerobic bacteria. Clindamycin is about eight times more active than lincomycin against Staphylococcus aureus and Streptococcus pneumonia. Clindamycin is four times more active than erythromycin against S. aureus and is active even against strains that are resistant to erythromycin, penicillin, and methicillin. Clindamycin is active against gram-positive anaerobes. Clindamycin highly activates against Bacteroides specie. [2] Clindamyci also alters the bacterial surface in such a way that phagocytosis and intracellular killing of the bacteria is greatly facilitated. Clindamycin potentiates opsonization and phagocytosis. [4]

In vivo Clindamycin (50mg/kg daily administrated by intramuscular) increases the survival rate of monkeys infected with penicillin-resistant S. aureu to 87.5% (7/8). [5] Clindamycin (40 mg/kg administrated three times daily) protects 87.5% (7/8) of rabbits from anaerobic pulmonary infections induced by transtracheal inoculation of a mixture of B. fragillis, Streptococcus morbillorm, Fusobacterium nucleatum and Eubacterium lentum. [6] Clindamycin (400 mg/kg treated by mixed in the diet) increases survival rate of mice infected with the Toxoplasma gondii to 100%, while all animals die in untreated group. [7]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 85 mg/mL
(200.0 mM)
Water Insoluble
Ethanol '85 mg/mL

Chemical Information

Molecular Weight 424.98


CAS No. 18323-44-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04946500 Active not recruiting -- Prosthetic Joint Infection|Staphylococcus University Hospital Brest May 15 2021 --
NCT04220918 Recruiting -- Medication Adherence|Medication Reaction Children''s Hospital of Philadelphia|National Institute on Deafness and Other Communication Disorders (NIDCD)|Monell Chemical Senses Center February 14 2020 --
NCT03845790 Recruiting Other: Blood and microdialysis samples Surgical Site Infection Poitiers University Hospital May 26 2019 Phase 1
NCT02782078 Completed Biological: Clindamycin and rifampicin dosages Staphylococcal Infections Assistance Publique - Hôpitaux de Paris March 6 2017 Not Applicable

(data from, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Clindamycin | Clindamycin ic50 | Clindamycin price | Clindamycin cost | Clindamycin solubility dmso | Clindamycin purchase | Clindamycin manufacturer | Clindamycin research buy | Clindamycin order | Clindamycin mouse | Clindamycin chemical structure | Clindamycin mw | Clindamycin molecular weight | Clindamycin datasheet | Clindamycin supplier | Clindamycin in vitro | Clindamycin cell line | Clindamycin concentration | Clindamycin nmr